Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13409986 | 0.90 | CYP3A4 (0.46) | KMT2ATSHRMEN1 | |
| SCHEMBL13409046 | 0.90 | ALDH1A1 (0.48) | KMT2ATSHRMEN1ALDH1A1LMNA | |
| SCHEMBL13409979 | 0.89 | KMT2A (0.55) | KMT2ATSHRMEN1ALDH1A1NPSR1 | |
| SCHEMBL14387701 | 0.89 | KDM4E (0.48) | L3MBTL1KMT2ATSHRMEN1ALDH1A1 | |
| SCHEMBL13409679 | 0.89 | PRKAA2 (0.49) | KMT2AMEN1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL13409748 | 0.88 | CYP3A4 (0.46) | KMT2ATSHRMEN1 | |
| SCHEMBL13409117 | 0.88 | ACKR3 (0.47) | L3MBTL1KMT2ATSHRMEN1ALDH1A1 | |
| SCHEMBL13409121 | 0.88 | L3MBTL1 (0.47) | L3MBTL1KMT2ATSHRMEN1ALDH1A1 | |
| SCHEMBL13409111 | 0.88 | KMT2A (0.51) | KMT2ATSHRMEN1ALDH1A1LMNA | |
| SCHEMBL13409686 | 0.87 | PRKAB2 (0.45) | KMT2ATSHRMEN1GAAACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | SCHERING CORPORATION SECHERING-PLOUGH CORPORATION (US) | 2010-04-15 | — | — | US | disclosed |
| US-7300941-B2 | Non-imidazole compounds | SCHERING CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | GPR119, ATF4, GID4 | L3MBTL1 4138/4885KMT2A 3430/4885TSHR 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.